China Universal Asset Management Company’s Cartesian Therapeutics RNAC Stock Holding History

China Universal Asset Management Company’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,558	Closed	-$46.6K	–	525
2025 Q3	$46.6K	Sell	4,558 -655	-13%	-$7.36K	﹤0.01%	438
2025 Q2	$54.2K	Buy	5,213 +115	+2%	+$1.23K	0.01%	413
2025 Q1	$67.2K	Sell	5,098 -291	-5%	-$5.2K	0.01%	391
2024 Q4	$96.5K	Buy	+5,389	New	+$109K	0.01%	395
2023 Q4	–	Sell	-131	Closed	-$4.17K	–	474
2023 Q3	$4.17K	Buy	131 +64	+96%	+$2.14K	﹤0.01%	400
2023 Q2	$2.25K	Sell	67 -2	-3%	-$72	﹤0.01%	423
2023 Q1	$2.88K	Buy	69 +17	+33%	+$799	﹤0.01%	417
2022 Q4	$1.76K	Buy	52 +4	+8%	+$170	﹤0.01%	381
2022 Q3	$2K	Buy	+48	New	+$2.64K	﹤0.01%	357

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

China Universal Asset Management Company's RNAC Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 4,558 shares — an estimated $46.6K sold.

China Universal Asset Management Company first reported a position in RNAC in Q3 2022 and held it in 9 quarters. The position peaked at $96.5K in Q4 2024. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

China Universal Asset Management Company reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
China Universal Asset Management Company sold 4,558 Cartesian Therapeutics shares in Q4 2025, an estimated $46.6K.
China Universal Asset Management Company first reported a position in Cartesian Therapeutics in Q3 2022 and held it in 9 quarters.
China Universal Asset Management Company's Cartesian Therapeutics position peaked at $96.5K in Q4 2024.
67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.